Skip to main content
. 2019 Apr 3;27(5):682–693. doi: 10.1016/j.jsps.2019.04.003

Fig. 4.

Fig. 4

A. 3D alignment of compound 4 (blue) and sunitinib (green) in the active site of VEGFR2. B. 2D presentation of the interactions between compound 4 and the active site of VEGFR2. C. 3D alignment of compound 4 (blue) and gefitinib (violet) in the active site of EGFR. D. 2D presentation of the interactions between compound 4 and the active site of EGFR. Hydrogen bonds are indicated as green dotted lines.